Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27743797 | 0.97 | CYP1A2 (0.50) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| Bromomethane SCHEMBL208626 | 0.93 | CYP1A2 (0.46) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| SCHEMBL17968493 | 0.80 | MAPT (0.56) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| SCHEMBL4028655 | 0.80 | KCNN4 (0.50) | CES1MAPTKMT2ACA1CA2 | |
| SCHEMBL27819946 | 0.80 | CYP1A2 (0.48) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| SCHEMBL354556 | 0.79 | CYP1A2 (0.52) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| SCHEMBL3629687 | 0.77 | CYP1A2 (0.50) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| SCHEMBL30274469 | 0.77 | CYP1A2 (0.50) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| SCHEMBL3669362 | 0.77 | CYP1A2 (0.50) | CYP1A2ALDH1A1TSHRPTPN1CES1 | |
| Water SCHEMBL9562304 | 0.77 | CYP1A2 (0.50) | CYP1A2ALDH1A1TSHRPTPN1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| CN-1275962-C | Novel anticholinergic agents that can be used as medicaments and method for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-09-20 | — | — | CN | disclosed |
| US-20060134007-A1 | Blister for inhalers | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| EP-1631569-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | Novartis AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2004096800-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040087617-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-6706726-B2 | QUATERNIZED DIARYLACETOXY-SUBSTITUTED NORTROPANE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-16 | — | — | US | disclosed |
| CN-1468236-A | Novel anticholinergic agents which can be used as medicaments and method for the production thereof | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-01-14 | — | — | CN | disclosed |
| US-20020115680-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | CYP1A2 1121/4885ALDH1A1 1477/4885TSHR 184/4885 |
| US-20020115680-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM2, CHRM1, CHRM5 | CYP1A2 152/4885ALDH1A1 1249/4885TSHR 1177/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP1A2 755/4885ALDH1A1 1767/4885TSHR 844/4885 |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM1, CHRM2, CHRM3 | CYP1A2 121/4885ALDH1A1 1436/4885TSHR 655/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ALDH1A1 3524/4885TSHR 1187/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ALDH1A1 3524/4885TSHR 1187/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CYP1A2 755/4885ALDH1A1 1767/4885TSHR 844/4885 |
| US-20040087617-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM1, CHRM2, CHRM5 | CYP1A2 207/4885ALDH1A1 838/4885TSHR 1075/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CYP1A2 3773/4885ALDH1A1 3524/4885TSHR 1187/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | CYP1A2 4536/4885ALDH1A1 2648/4885TSHR 1730/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CYP1A2 755/4885ALDH1A1 1767/4885TSHR 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.